ERASCA INC. DL -,0001 Aktie

Erasca placed 31,428,572 common shares at $17.50 per share and expects gross proceeds of about $550 million. The lead managers were granted a 30-day option to purchase up to 4,714,285 additional shares at the offering price. Net proceeds are intended to finance research and development, ongoing development programs and working capital; the closing of the transaction is expected on July 15, 2026. » More on de.investing.com

Erasca announced a guaranteed public placement of common stock totaling $500 million plus a 30‑day option for $75 million; the proceeds are intended for R&D and working capital, which triggered shareholder dilution concerns and sent the stock down about 3.1% in after‑hours trading. At the same time the company released updated phase‑1 data for ERAS‑0015: an unconfirmed overall response rate of 57% at eight weeks in patients with ductal pancreatic cancer and KRAS‑G12X mutation; recommended dose 32 mg once daily, with six of seven patients remaining on treatment. Goldman Sachs initiated coverage with an "Early‑Stage Biotech" rating and views Erasca as a leader in RAS targeting behind Revolution Medicines; ongoing litigation and a weak market backdrop heighten near‑term risks. » More on de.investing.com

Erasca intends to issue common shares in a syndicated public offering totaling $500 million and to grant the bookrunners a 30-day option to purchase additional shares worth up to $75 million. The securities will be offered under an S-3 shelf registration; J.P. Morgan, Morgan Stanley, Jefferies and Evercore ISI are leading the syndicate. Net proceeds and existing cash will be used to fund research and development, working capital and general corporate purposes. The announcement follows a strong share rally and a market capitalization of about $5.57 billion; the stock is rated overvalued in the analysis and the company remains unprofitable (EPS -$0.96). » More on de.investing.com